AllianceBernstein’s Orexigen Therapeutics, Inc. OREX Stock Holding History

AllianceBernstein’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-18,108	Closed	-$102K	–	3078
2016 Q1	$102K	Hold	18,108	–	–	﹤0.01%	2817
2015 Q4	$311K	Hold	18,108	–	–	﹤0.01%	2616
2015 Q3	$382K	Hold	18,108	–	–	﹤0.01%	2583
2015 Q2	$896K	Hold	18,108	–	–	﹤0.01%	2339
2015 Q1	$1.42M	Hold	18,108	–	–	﹤0.01%	1982
2014 Q4	$1.1M	Buy	18,108 +1,920	+12%	+$96.4K	﹤0.01%	2162
2014 Q3	$690K	Hold	16,188	–	–	﹤0.01%	2395
2014 Q2	$1M	Buy	16,188 +2,810	+21%	+$163K	﹤0.01%	2259
2014 Q1	$870K	Sell	13,378 -6	-0%	-$406	﹤0.01%	2230
2013 Q4	$754K	Buy	13,384 +2	+0%	+$112	﹤0.01%	2284
2013 Q3	$822K	Sell	13,382 -57	-0.4%	-$3.86K	﹤0.01%	2238
2013 Q2	$786K	Buy	+13,439	New	+$827K	﹤0.01%	2209

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AllianceBernstein's OREX Position: Q2 2016 in Review

AllianceBernstein sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 18,108 shares — an estimated $102K sold.

AllianceBernstein first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $1.42M in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

AllianceBernstein reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
AllianceBernstein sold 18,108 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $102K.
AllianceBernstein first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
AllianceBernstein's Orexigen Therapeutics, Inc. position peaked at $1.42M in Q1 2015.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on AllianceBernstein's 13F filing for Q2 2016, filed 11 Aug 2016.